Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Chronic Obstructive Pulmonary Disease Market: By Treatment, By Drug Class By Disease Type, By End Users and Geography
Chronic Obstructive Pulmonary Disease (COPD) Market size was valued at US$ 21.2 billion in 2023 and is poised to grow at a CAGR of 4.8% over 2024-2030. Chronic obstructive pulmonary disease (COPD) is a type of progressive lung disease characterized by long-term respiratory symptoms and airflow limitation, including symptoms such as shortness of breath and a cough, and the causes include tobacco smoking, air pollution, and genetics. Based on the drug class, the combination therapy segment is anticipated to dominate the market share over the forecast period.
According to the World Health Organization, COPD is the third leading cause of death worldwide, causing 3.23 million deaths in 2019. The increasing incidences of respiratory disorders and growing awareness will act as the chronic obstructive pulmonary disease market growth driver, whereas, the high cost of treatment would be the lagging factor for the market. The rise in chronic obstructive pulmonary disease market demand for novel drug therapies and an increase in investments by key market players are opportunities for the expansion of the market.
Study Period
2024-2030Base Year
2023CAGR
4.8%Largest Market
North AmericaFastest Growing Market
Asia Pacific
With an increase in the incidence of COPD, awareness programs, and adoption of effective treatments are also increasing, so the advancements in technologies for drug development are the major factors for the market growth. For instance, in Feb 2021, Sanofi, in collaboration with Regeneron Pharmaceuticals, initiated a phase-III clinical trial for Itepekimab, in moderate-to-severe COPD. Thus, the increased awareness, research, and development for chronic disorders will lead to the growth of the market within the forecast period. However, side effects and risks associated with COPD drugs could be a negative factor for the market growth.
Report Benchmarks |
Details |
Report Study Period |
2024-2030 |
Market Size in 2023 |
US$ 21.2 billion |
Market CAGR |
4.8% |
By Treatment |
|
By Drug Class |
|
By Disease Type |
|
By End User |
|
Download Free Sample Report
The global chronic obstructive pulmonary disease market size was valued at US$ 21.2 billion in 2023 and is projected to grow at a CAGR of 4.8% by 2030.
The rise in demand for novel drug therapies and an increase in investments are the key opportunities for the Chronic Obstructive Pulmonary Disease (COPD) market.
The increasing incidences of respiratory disorders and growing awareness are the growth drivers in the Chronic Obstructive Pulmonary Disease (COPD) market.
Boehringer Ingelheim International GmbH, GlaxoSmithKline plc., Novartis International AG, AstraZeneca, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Merck & Co., Amneal Pharmaceuticals LLC., Mylan N.V., and OptiNose US Inc. are a few companies operating in the Chronic Obstructive Pulmonary Disease (COPD) market.
1.Executive Summary |
2.Global Chronic Obstructive Pulmonary Disease Market Introduction |
2.1.Global Chronic Obstructive Pulmonary Disease Market - Taxonomy |
2.2.Global Chronic Obstructive Pulmonary Disease Market - Definitions |
2.2.1.Treatment |
2.2.2.Drug Class |
2.2.3.Disease Type |
2.2.4. End User |
2.2.5.Region |
3.Global Chronic Obstructive Pulmonary Disease Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Product Landscape |
3.6. New Product Launches |
3.7. Impact of COVID 19 on Market |
4.Global Chronic Obstructive Pulmonary Disease Market Analysis, 2019 - 2023 and Forecast 2024 - 2030 |
4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5.Global Chronic Obstructive Pulmonary Disease Market By Treatment, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
5.1. Drugs |
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. Surgery |
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
5.3. Oxygen Therapy |
5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.3. Market Opportunity Analysis |
5.4. Others |
5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.4.3. Market Opportunity Analysis |
6.Global Chronic Obstructive Pulmonary Disease Market By Drug Class, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
6.1. Combination Therapy |
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Bronchodilators |
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
6.3. Corticosteroids |
6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.3.3. Market Opportunity Analysis |
6.4. Phosphodiesterase Type 4 Inhibitor |
6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.4.3. Market Opportunity Analysis |
6.5. Mucokinetics |
6.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.5.3. Market Opportunity Analysis |
6.6. Others |
6.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.6.3. Market Opportunity Analysis |
7.Global Chronic Obstructive Pulmonary Disease Market By Disease Type, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
7.1. Chronic Bronchitis |
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Emphysema |
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
8.Global Chronic Obstructive Pulmonary Disease Market By End User, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
8.1. Hospitals |
8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.1.3. Market Opportunity Analysis |
8.2. Clinics |
8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.2.3. Market Opportunity Analysis |
8.3. Homecare |
8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.3.3. Market Opportunity Analysis |
8.4. Others |
8.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.4.3. Market Opportunity Analysis |
9.Global Chronic Obstructive Pulmonary Disease Market By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
9.1. North America |
9.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
9.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.1.3. Market Opportunity Analysis |
9.2. Europe |
9.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
9.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.2.3. Market Opportunity Analysis |
9.3. Asia Pacific (APAC) |
9.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
9.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.3.3. Market Opportunity Analysis |
9.4. Middle East and Africa (MEA) |
9.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
9.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.4.3. Market Opportunity Analysis |
9.5. Latin America |
9.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
9.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.5.3. Market Opportunity Analysis |
10.North America Chronic Obstructive Pulmonary Disease Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
10.1. Treatment Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.1.1.Drugs |
10.1.2.Surgery |
10.1.3.Oxygen Therapy |
10.1.4.Others |
10.2. Drug Class Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.2.1.Combination Therapy |
10.2.2.Bronchodilators |
10.2.3.Corticosteroids |
10.2.4.Phosphodiesterase Type 4 Inhibitor |
10.2.5.Mucokinetics |
10.2.6.Others |
10.3. Disease Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.3.1.Chronic Bronchitis |
10.3.2.Emphysema |
10.4. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.4.1.Hospitals |
10.4.2.Clinics |
10.4.3.Homecare |
10.4.4.Others |
10.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.5.1.United States of America (USA) |
10.5.2.Canada |
11.Europe Chronic Obstructive Pulmonary Disease Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
11.1. Treatment Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.1.1.Drugs |
11.1.2.Surgery |
11.1.3.Oxygen Therapy |
11.1.4.Others |
11.2. Drug Class Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.2.1.Combination Therapy |
11.2.2.Bronchodilators |
11.2.3.Corticosteroids |
11.2.4.Phosphodiesterase Type 4 Inhibitor |
11.2.5.Mucokinetics |
11.2.6.Others |
11.3. Disease Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.3.1.Chronic Bronchitis |
11.3.2.Emphysema |
11.4. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.4.1.Hospitals |
11.4.2.Clinics |
11.4.3.Homecare |
11.4.4.Others |
11.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.5.1.Germany |
11.5.2.France |
11.5.3.Italy |
11.5.4.United Kingdom (UK) |
11.5.5.Spain |
12.Asia Pacific (APAC) Chronic Obstructive Pulmonary Disease Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
12.1. Treatment Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.1.1.Drugs |
12.1.2.Surgery |
12.1.3.Oxygen Therapy |
12.1.4.Others |
12.2. Drug Class Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.2.1.Combination Therapy |
12.2.2.Bronchodilators |
12.2.3.Corticosteroids |
12.2.4.Phosphodiesterase Type 4 Inhibitor |
12.2.5.Mucokinetics |
12.2.6.Others |
12.3. Disease Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.3.1.Chronic Bronchitis |
12.3.2.Emphysema |
12.4. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.4.1.Hospitals |
12.4.2.Clinics |
12.4.3.Homecare |
12.4.4.Others |
12.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.5.1.China |
12.5.2.India |
12.5.3.Australia and New Zealand (ANZ) |
12.5.4.Japan |
12.5.5.Rest of APAC |
13.Middle East and Africa (MEA) Chronic Obstructive Pulmonary Disease Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
13.1. Treatment Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.1.1.Drugs |
13.1.2.Surgery |
13.1.3.Oxygen Therapy |
13.1.4.Others |
13.2. Drug Class Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.2.1.Combination Therapy |
13.2.2.Bronchodilators |
13.2.3.Corticosteroids |
13.2.4.Phosphodiesterase Type 4 Inhibitor |
13.2.5.Mucokinetics |
13.2.6.Others |
13.3. Disease Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.3.1.Chronic Bronchitis |
13.3.2.Emphysema |
13.4. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.4.1.Hospitals |
13.4.2.Clinics |
13.4.3.Homecare |
13.4.4.Others |
13.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.5.1.GCC Countries |
13.5.2.South Africa |
13.5.3.Rest of MEA |
14.Latin America Chronic Obstructive Pulmonary Disease Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
14.1. Treatment Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
14.1.1.Drugs |
14.1.2.Surgery |
14.1.3.Oxygen Therapy |
14.1.4.Others |
14.2. Drug Class Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
14.2.1.Combination Therapy |
14.2.2.Bronchodilators |
14.2.3.Corticosteroids |
14.2.4.Phosphodiesterase Type 4 Inhibitor |
14.2.5.Mucokinetics |
14.2.6.Others |
14.3. Disease Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
14.3.1.Chronic Bronchitis |
14.3.2.Emphysema |
14.4. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
14.4.1.Hospitals |
14.4.2.Clinics |
14.4.3.Homecare |
14.4.4.Others |
14.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
14.5.1.Brazil |
14.5.2.Mexico |
14.5.3.Rest of LA |
15. Competition Landscape |
15.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
15.2.1.Boehringer Ingelheim International GmbH |
15.2.2.GlaxoSmithKline plc. |
15.2.3.Novartis International AG |
15.2.4.AstraZeneca |
15.2.5.Pfizer Inc. |
15.2.6.Teva Pharmaceutical Industries Ltd. |
15.2.7.Merck & Co. |
15.2.8.Amneal Pharmaceuticals LLC. |
15.2.9.Mylan N.V. |
15.2.10.OptiNose US Inc. |
16. Research Methodology |
17. Appendix and Abbreviations |
Key Market Players